151 related articles for article (PubMed ID: 28818446)
21. A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies.
Borisa AC; Bhatt HG
Eur J Med Chem; 2017 Nov; 140():1-19. PubMed ID: 28918096
[TBL] [Abstract][Full Text] [Related]
22. A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.
Aliagas-Martin I; Burdick D; Corson L; Dotson J; Drummond J; Fields C; Huang OW; Hunsaker T; Kleinheinz T; Krueger E; Liang J; Moffat J; Phillips G; Pulk R; Rawson TE; Ultsch M; Walker L; Wiesmann C; Zhang B; Zhu BY; Cochran AG
J Med Chem; 2009 May; 52(10):3300-7. PubMed ID: 19402633
[TBL] [Abstract][Full Text] [Related]
23. Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors.
Uitdehaag JC; de Roos JA; Prinsen MB; Willemsen-Seegers N; de Vetter JR; Dylus J; van Doornmalen AM; Kooijman J; Sawa M; van Gerwen SJ; de Man J; Buijsman RC; Zaman GJ
Mol Cancer Ther; 2016 Dec; 15(12):3097-3109. PubMed ID: 27587489
[TBL] [Abstract][Full Text] [Related]
24. Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor.
Farrell P; Shi L; Matuszkiewicz J; Balakrishna D; Hoshino T; Zhang L; Elliott S; Fabrey R; Lee B; Halkowycz P; Sang B; Ishino S; Nomura T; Teratani M; Ohta Y; Grimshaw C; Paraselli B; Satou T; de Jong R
Mol Cancer Ther; 2013 Apr; 12(4):460-70. PubMed ID: 23358665
[TBL] [Abstract][Full Text] [Related]
25. The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells.
Li JP; Yang YX; Liu QL; Zhou ZW; Pan ST; He ZX; Zhang X; Yang T; Pan SY; Duan W; He SM; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1027-62. PubMed ID: 25733818
[TBL] [Abstract][Full Text] [Related]
26. Optimization and biological evaluation of nicotinamide derivatives as Aurora kinase inhibitors.
Qi B; Xu X; Yang Y; He H; Yue X
Bioorg Med Chem; 2019 Sep; 27(17):3825-3835. PubMed ID: 31307762
[TBL] [Abstract][Full Text] [Related]
27. Multi-kinase inhibitors, AURKs and cancer.
Cicenas J; Cicenas E
Med Oncol; 2016 May; 33(5):43. PubMed ID: 27038473
[TBL] [Abstract][Full Text] [Related]
28. Facile identification of dual FLT3-Aurora A inhibitors: a computer-guided drug design approach.
Chang Hsu Y; Ke YY; Shiao HY; Lee CC; Lin WH; Chen CH; Yen KJ; Hsu JT; Chang C; Hsieh HP
ChemMedChem; 2014 May; 9(5):953-61. PubMed ID: 24665000
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological evaluation of nitroxide labeled pyrimidines as Aurora kinase inhibitors.
Ma YZ; Tang ZB; Sang CY; Qi ZY; Hui L; Chen SW
Bioorg Med Chem Lett; 2019 Mar; 29(5):694-699. PubMed ID: 30728112
[TBL] [Abstract][Full Text] [Related]
30. Structural Biology Insight for the Design of Sub-type Selective Aurora Kinase Inhibitors.
Sarvagalla S; Coumar MS
Curr Cancer Drug Targets; 2015; 15(5):375-93. PubMed ID: 25895501
[TBL] [Abstract][Full Text] [Related]
31. Discovery of Inhibitors of Aurora/PLK Targets as Anticancer Agents.
Qi B; Zhong L; He J; Zhang H; Li F; Wang T; Zou J; Lin YX; Zhang C; Guo X; Li R; Shi J
J Med Chem; 2019 Sep; 62(17):7697-7707. PubMed ID: 31381325
[TBL] [Abstract][Full Text] [Related]
32. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
Shimomura T; Hasako S; Nakatsuru Y; Mita T; Ichikawa K; Kodera T; Sakai T; Nambu T; Miyamoto M; Takahashi I; Miki S; Kawanishi N; Ohkubo M; Kotani H; Iwasawa Y
Mol Cancer Ther; 2010 Jan; 9(1):157-66. PubMed ID: 20053775
[TBL] [Abstract][Full Text] [Related]
33. Benzochalcones bearing pyrazoline moieties show anti-colorectal cancer activities and selective inhibitory effects on aurora kinases.
Shin SY; Yoon H; Hwang D; Ahn S; Kim DW; Koh D; Lee YH; Lim Y
Bioorg Med Chem; 2013 Nov; 21(22):7018-24. PubMed ID: 24095020
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of novel benzoxazole analogs as Aurora B kinase inhibitors.
An Y; Lee E; Yu Y; Yun J; Lee MY; Kang JS; Kim WY; Jeon R
Bioorg Med Chem Lett; 2016 Jul; 26(13):3067-3072. PubMed ID: 27209235
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and bioevaluation of N-trisubstituted pyrimidine derivatives as potent aurora A kinase inhibitors.
Luo Y; Deng YQ; Wang J; Long ZJ; Tu ZC; Peng W; Zhang JQ; Liu Q; Lu G
Eur J Med Chem; 2014 May; 78():65-71. PubMed ID: 24681066
[TBL] [Abstract][Full Text] [Related]
36. BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells.
Cheung CH; Lin WH; Hsu JT; Hour TC; Yeh TK; Ko S; Lien TW; Coumar MS; Liu JF; Lai WY; Shiao HY; Lee TR; Hsieh HP; Chang JY
PLoS One; 2011; 6(8):e23485. PubMed ID: 21887256
[TBL] [Abstract][Full Text] [Related]
37. Aurora-B kinase inhibitors for cancer chemotherapy.
Yeung SC; Gully C; Lee MH
Mini Rev Med Chem; 2008 Dec; 8(14):1514-25. PubMed ID: 19075809
[TBL] [Abstract][Full Text] [Related]
38. Multicomponent reactions in antimitotic drug discovery.
Cores A; Carbajales C; Coelho A
Curr Top Med Chem; 2014; 14(20):2209-30. PubMed ID: 25440494
[TBL] [Abstract][Full Text] [Related]
39. Toward
Dalva-Aydemir S; Akyerli CB; Yüksel ŞK; Keskin H; Yakıcıer MC
OMICS; 2019 Oct; 23(10):486-495. PubMed ID: 31549911
[TBL] [Abstract][Full Text] [Related]
40. Discovery and evaluation of 3,5-disubstituted indole derivatives as Pim kinase inhibitors.
More KN; Hong VS; Lee A; Park J; Kim S; Lee J
Bioorg Med Chem Lett; 2018 Aug; 28(14):2513-2517. PubMed ID: 29871845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
